ClinicalTrials.gg
RecruitingNCT07407465CHIMERAUpdated Feb 17, 2026

Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.

A Phase 2 interventional study of Trastuzumab-Deruxtecan (T-DXd) and Capecitabine in Colorectal Cancer, Colorectal Adenocarcinoma and Rectal Adenocarcinoma, sponsored by Gruppo Oncologico del Nord-Ovest. Recruiting at 28 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Gruppo Oncologico del Nord-Ovest · Phase 2, Interventional, and Treatment

How we know · 8 judgments

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 179 studies testing capecitabine in Colorectal Neoplasms — 24 open to participants now, 32 under way, 7 of them phase 3. Capecitabine · Colorectal Neoplasms.

Planned enrollment
110th of 173
42 · median 55
Started
2025
with 4 others
Phase 2
100 of 179
16 open now
Primary completion
2027-10
later than 23 of 31 live
Registered
172nd of 179
by date
Lead sponsor
3 of 179
Gruppo Oncologico del Nord-Ovest

Among the 179 studies testing capecitabine in Colorectal Neoplasms, this one is the 110th largest by planned enrollment of the 173 interventional ones that give a count, is one of 5 that started in 2025, is one of 100 in phase 2, reaches primary completion later than 23 of the 31 other live ones, and was the 172nd registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

24 of the 179 studies testing capecitabine in Colorectal Neoplasms are open now, in 9 countries. Recruiting first, the newest first:

18 more — sign in →

By country, each count listing its studies:

All 24 open studies →

About capecitabine

Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 179 studies testing capecitabine in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The aim of this study is to evaluate the activity of first-line trastuzumab-deruxtecan, capecitabine and bevacizumab in terms of overall response rate for patients with HER-2 positive metastatic/locally advanced unresectable colorectal cancer

Read the detailed description

This is a multinational, Open-label, Single-arm Phase II trial in which patients with metastatic or locally advanced unresectable HER-2 positive colorectal cancer will receive upfront trastuzumab-deruxtecan, capecitabine and bevacizumab until progressive disease, unacceptable toxicity, consent withdrawal, investigator's decision or study termination, whichever occurs first. The primary endpoint of the study is Overall Response Rate by blinded independent central review. In order to preliminarily assess safety, a safety run-in phase will be conducted. The safety run-in phase will include the first 6 patients enrolled. After 6 patients will have received 3 cycles of study treatment, enrollment will be interrupted. A Safety Monitoring Committee (SMC) will review safety data (including demographics, adverse events, serious adverse events, adverse events of special interest, and relevant laboratory data). The SMC will then provide a recommendation as to whether the study may continue, whether amendment(s) to the protocol should be implemented, or whether the study should be stopped. Recruitment will only be resumed accordingly to SMC decision.

03

Conditions studied

  • Colorectal Cancer
  • Colorectal Adenocarcinoma
  • Rectal Adenocarcinoma
  • Rectal Cancer, Adenocarcinoma
  • Rectal Cancer, Metastatic
  • Colon Cancer Metastatic
  • Colon Cancer Adenocarcinoma

Keywords

  • colorectal cancer
  • HER-2 positive
  • Trastuzumab-deruxtecan
  • Capecitabine
  • Bevacizumab
  • mCRC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written obtained from the patient/legal representative before performing any protocol-related procedures, including screening evaluations.
  • Patient state to comply with all the study procedures and treatments. Patients must be accessible for treatment and follow-up. Patients registered for this trial must be treated and followed at the participating Centre.
  • Age ≥ 18 years at the time of informed consent.
  • Performance Status ≤ 2.
  • of ≥ 3 months.
  • Have documented adenocarcinoma of the colon or rectum, which is initially or unresectable locally advanced.
  • Subjects must be willing to provide the most recently available formalin-fixed paraffin-embedded tumor tissue blocks (or at least 25 freshly sectioned slides) for translational analyses (sampled before 1st treatment course). If is not available for testing or for exploratory aims, then a newly obtained baseline biopsy of an accessible tumor lesion is required before Cycle 1 Day 1 timeframe. Biopsy must contain adequate tissue for analysis; the following biopsy types are acceptable: resection, excision, punch (skin lesions only) and core needle biopsies.
  • Presence of locally determined HER2 overexpression/amplification defined as IHC 3+ or 2+/ISH amplified on archival/newly obtained tumor tissue, according to the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines for gastric/gastroesophageal cancer.
  • Have RAS known status and pMMR/MSS status by standard local testing.
  • Have radiographically per v1.1.
  • Have adequate hematological, hepatic, renal, cardiac and coagulation function, as defined below, obtained ≤ 7 days prior to enrollment (Cycle 1 Day 1):

    • (ANC) ≥ 1500/mm3. (Granulocyte-colony stimulating factor administration is not allowed within 1 week prior to C1D1).
    • count ≥ 100000/mm3. (Platelet transfusion is not allowed within 1 week prior to C1D1)
    • ≥ 9.0 g/dL
    • Total ≤ 1.5 x (ULN) or ≤ 3 x ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) or liver metastases at baseline.
    • (AST) and alanine aminotransferase (ALT) ≤ 3 x ULN (≤ 5 x ULN if liver metastases are present).
    • Serum albumin ≥ 2.5 g/dL.
    • ≥ 60 mL/min as determined by Cockcroft-Gault (using actual body weight).
    • (LVEF) ≥ 50% within 28 days before enrollment.
    • or Prothrombin time and either partial thromboplastin or activated partial thromboplastin time ≤ 1.5 x ULN.
  • Have had adequate from previous treatment before screening, defined as:

    • ≥ 4 weeks from major surgery.
    • ≥ 4 weeks from radiation therapy, including palliative stereotactic radiation therapy to the chest.
    • ≥ 3 weeks from anti-cancer chemotherapy [immunotherapy (non-antibody-based therapy)], retinoid therapy, hormonal therapy.
    • ≥ 4 weeks from antibody-based anti-cancer therapy
    • ≥ 2 weeks or 5 half-lives (whichever is longer) from targeted agent- and small molecule-based therapy
    • ≥ 6 weeks from nitrosureas or mitomycin C
    • ≥ 1 week from TKIs approved for treatment of patients with non-small-cell lung cancer (baseline CT must be completed after discontinuation of TKI)
    • > 2 weeks from chloroquine/hydroxychloroquine
    • ≥ 2 weeks from cell-free and Concentrated Ascites Reinfusion Therapy (CART), peritoneal shunt or drainage of ascites, pleural or pericardial effusion.
  • Evidence of status or negative serum pregnancy test for females of who are sexually active with a non-sterilized male partner. For women of childbearing potential, a negative result for serum pregnancy test (test must have a sensitivity of at least 25 mIU/mL) must be available at the screening visit and urine beta- human chorionic gonadotropin (β-HCG) pregnancy test prior to each administration of IP. Women of childbearing potential are defined as those who are not surgically sterile (i.e. underwent bilateral salpingectomy, bilateral oophorectomy, or complete hysterectomy) or post-menopausal. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause.
  • Female patients of childbearing potential who are sexually active with a non-sterilized male partner must use at least one highly effective method of , presented in Table 1. From the time of screening and must agree to continue using such precautions for 7 months after the last dose of product (IP). Not all methods of contraception are highly effective. Female patients must refrain from breastfeeding while on study and for 7 months after the last dose of IP. Complete heterosexual abstinence for the duration of the study and drug washout period is an acceptable contraceptive method if it is line with the patient's usual lifestyle (consideration must be made to the duration of the clinical trial); however, periodic, or occasional abstinence, the rhythm method, and the withdrawal method are not acceptable.
  • Female participants must not donate, or retrieve for their own use, ova from the time of enrolment and throughout the study treatment period, and for at least 7 months after the final study drug administration. They should refrain from breastfeeding throughout this time. Preservation of ova may be considered prior to enrollment in this study.
  • Non-sterilized male patients who are sexually active with a female partner of childbearing potential must use a condom with spermicide from screening to 4 months after the final dose of IP for T-DXd while 6 months for capecitabine and bevacizumab. Complete heterosexual abstinence for the duration of the study and drug washout period is an acceptable contraceptive method if it is in line with the patient's usual lifestyle (consideration must be made to the duration of the clinical trial); however, periodic or occasional abstinence, the rhythm method, and the withdrawal method are not acceptable. It is strongly recommended for the female partners of a male patient to also use at least one highly effective method of contraception throughout this period, by employing protocol-recommended methods. In addition, male patients should refrain from fathering a child, or freezing or donating sperm from the time of randomization/enrollment, throughout the study and for 4 months after the last dose of IP for T-DXd while 6 months for capecitabine and bevacizumab. Preservation of sperm should be considered prior to enrollment in this study.

Exclusion criteria

Exclusion Criteria:

  • Have previously received any systemic anticancer therapy for CRC in the /locally advanced unresectable setting or have participated in any interventional clinical trial for CRC in the metastatic/locally advanced unresectable setting. Subjects may have received prior fluoropyrimidine with or without oxaliplatin for CRC in the or neoadjuvant setting if it was completed > 6 months before enrollment.
  • Has spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy with or anticonvulsants to control associated symptoms. Subjects with clinically inactive may be included in the study. Subjects with treated brain metastases that are no longer symptomatic and who require no treatment with corticosteroids or anticonvulsants may be included in the study if they have recovered from the acute toxic effect of radiotherapy. A minimum of 2 weeks must have elapsed between the end of whole brain radiotherapy and study enrollment.
  • Have previously been treated with an anti- agent and/or a topoisomerase I inhibitor.
  • Lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome, or inability to take oral medications.
  • Have substance abuse or any other medical conditions such as cardiac or psychological conditions, that may, in the opinion of the investigator, interfere with the subject's participation in the clinical study or evaluation of the clinical study results.
  • Patients with a medical history of myocardial infarction (MI) within 6 months before enrollment, symptomatic congestive heart failure (CHF) ( Class II to IV). Subjects with troponin levels above at screening (as defined by the manufacturer) and without any myocardial-related symptoms should undergo a cardiologic consultation before enrollment to rule out MI.
  • interval (QTcF) prolongation to > 470 msec (females) or > 450 msec (males) based on average of the screening 12-lead .
  • Symptomatic arterial hypertension or uncontrolled arterial hypertension, as determined by the investigator.
  • Have a history of (non-infectious) ILD/pneumonitis that required steroids, have current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
  • Lung-specific intercurrent clinically significant illnesses including, but not limited to, any underlying pulmonary disorder (e.g., severe asthma, severe [COPD], restrictive lung disease, pleural effusion, etc.).
  • Any , connective tissue, or inflammatory disorders (e.g., Rheumatoid arthritis, Sjögren's, sarcoidosis etc.) where there is documented, or a suspicion of, pulmonary involvement at the time of screening. Full details of the disorder should be recorded in the eCRF for patients who are included in the study.
  • Prior pneumonectomy (complete).
  • A pleural effusion, ascites or pericardial effusion that requires drainage, peritoneal shunt, or Cell-free and Concentrated Ascites Reinfusion Therapy (CART).
  • Have unresolved toxicities from previous anticancer therapy, defined as toxicity (other than alopecia) not yet resolved to Grade ≤ 1 or baseline. Subjects may be enrolled with chronic, stable Grade 2 toxicities (defined as no worsening to Grade > 2 for at least 3 months before enrollment/cycle 1 day 1 and managed with standard of care treatment) that the investigator deems related to previous anticancer therapy such as: chemotherapy-induced neuropathy and fatigue.
  • Patients with known to the study drug or to its .
  • Patients with known hypersensitivity to other monoclonal antibodies.
  • Pregnant or breastfeeding female patients, or patients who are planning to become pregnant. Sexually active men not willing to use adequate during whole study period.
  • Previous or concurrent within 3 years of study entry. Exceptions are adequately resected non-melanoma skin cancer, curatively treated in-situ diseases, and other solid tumors that have been curatively treated.
  • Presence of any of the following dihydropyrimidine dehydrogenase (DPYD) polymorphism, based on local laboratory testing: DPYD 2a (c.1905+1G>A); DPYD13 (c.1679 T>G); DPYD D949V (c.2846 A>T). French and German patients may undergo baseline uracilemia assessment as detailed below in spite of polymorphism testing.
  • Have a history of , cerebrovascular accident, myocardial infarction, unstable angina, cardiac or other vascular stenting, angioplasty, or cardiac surgery within 6 months prior to enrollment (Cycle 1 Day 1).
  • Have a history of a significant bleeding event (e.g., bleeding needing medical intervention) within 6 months prior to enrollment (Cycle 1 Day 1) unless the source of bleeding has been definitively treated.
  • Have a history of GI perforation within 12 months prior to enrollment (Cycle 1 Day 1).
  • Major surgical procedure or significant traumatic injury ≤ 28 days prior to enrollment (≤ 56 days for hepatectomy, open thoracotomy or major neurosurgery) or anticipation of need for major surgical procedure during the course of the study.
  • Serious, non-healing wound, ulcer, or bone fracture.
  • Prior organ transplantation, including allogenic stem-cell transplantation.
  • Known history of infection.
  • Active infection including tuberculosis, , . Patients positive for hepatitis C (HCV) antibody are eligible only if HCV RNA polymerase chain reaction (PCR) is negative. Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible only if meeting the following criteria:

    • HBsAg negativity (for more than 6 months off anti-viral treatment).
    • Anti-HBc positivity (IgG or total Ig).
    • Absence of cirrhosis or fibrosis on prior imaging or .
    • Absence of HCV co-infection and no history of HCV co-infection.
    • Access to a local HBV expert during and after the study Patients meeting all abovementioned criteria must be closely monitored for HBV reactivation.
  • Receipt of live, attenuated vaccine (mRNA and replication deficient adenoviral vaccines are not considered attenuated ) within 30 days prior to the first dose of trastuzumab deruxtecan. Note: Patients, if enrolled, should not receive live vaccine during the study and up to 30 days after the last dose of IMP
  • Any psychiatric condition that would prohibit the understanding or rendering of and that would limit compliance with trial requirements.
  • Use of any disallowed drugs (see Section 7.5).

Additional exclusion criteria for France and Germany:

  • Patients with dihydropyrimidine dehydrogenase (DPD) enzyme deficiency (uracilemia ≥ 16 ng/mL)
  • Patient who is under judicial protection and patient who is legally institutionalized or under guardianship or not able to give consent.
Terms in these criteria, in plain language(40)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    Trastuzumab-deruxtecan, capecitabine, bevacizumab

    * Trastuzumab-deruxtecan 5.4 mg/Kg, IV, d1 q3w; * Capecitabine 1000 mg/sqm B.I.D, oral, dd1-14 q3w; * Bevacizumab 7.5 mg/kg, IV, d1 q3w; Treatment will be received until progressive disease, unacceptable toxicity, consent withdrawal, investigator's decision or study termination, whichever occurs first.

    Drug: Trastuzumab-Deruxtecan (T-DXd) · Drug: Capecitabine · Drug: Bevacizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Response Rate

    Overall response rate will be defined as the proportion of patients who achieve either a partial or complete response as best responses to study treatment according to RECIST v1.1 criteria. Response will be assessed as per blinded independent central review

    Time frame: 24 months

Secondary outcomes

  1. Progression-free survival

    Progression-free survival is defined as the time from treatment start to radiological evidence of disease progression (as per RECIST v1.1 criteria) or death, whichever occurs first. PFS will be assessed by BICR and Investigator-assessed.

    Time frame: 24 months

  2. Overall survival

    Overall survival is defined as the time from treatment start to death.

    Time frame: 48 months

  3. Treatment safety

    Treatment safety is defined as the incidence of adverse events during treatment and follow-up, assessed according to CTCAE v5.0.

    Time frame: 24 months

  4. Disease control rate

    Disease control rate (DCR) by BICR and Investigator assessment, defined as the proportion of subjects achieving a complete response (CR), partial response (PR) or stable disease (SD) as best response during study treatment, as per RECIST v1.1.

    Time frame: 24 months

  5. Early tumor shrinkage

    Early tumor shrinkage (ETS), defined as the proportion of patients achieving a reduction in tumor size of at least 20% at first radiological reassessment.

    Time frame: 24 months

  6. Duration of response

    Duration of response (DOR), defined as the time from first radiological evidence of complete or partial response to disease progression or death whichever occurs first.

    Time frame: 24 months

  7. Depth of response

    Depth of response (DoR) defined as the maximum percentage of tumor shrinkage at best response relative to baseline.

    Time frame: 24 months

  8. CEA dynamics

    Serum carcinoembryonic antigen (CEA) concentration will be measured in peripheral blood using standard-of-care clinical laboratory immunoassays performed at participating sites. The unit of measure will be ng/mL. CEA kinetics will be summarized as: (i) absolute CEA values (ng/mL) over time; (ii) change from baseline (absolute and percent change); and (iii) CEA normalization (conversion to within institutional normal range) when applicable. CEA dynamics will be assessed at baseline, every 9 (+/-1) weeks during treatment, at EOT and during follow-up visits through 24 months. Associations will be explored between CEA kinetics and efficacy/activity outcomes including objective response (per RECIST v1.1), duration of response, progression-free survival and overall survival, using correlation/association analyses

    Time frame: 24 months

  9. Central review of HER-2 status

    Tumor HER2 status will be centrally assessed on archival tumor tissue on which local HER-2 positivity was assessed. HER-2 testing will be performed by means of immunohistochemistry (IHC) assay with in situ hybridization (ISH) in case of IHC 2+ scores. HER2 status will be evaluated according to the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines for gastric/gastroesophageal cancer. The measure will be reported as HER2 IHC score category, ISH result (where applicable), and overall central HER2 status (positive vs negative). Concordance between central and local HER2 results will be evaluated using percent agreement (overall/positive/negative agreement as applicable) and Cohen's kappa statistic. Exploratory associations between centrally confirmed HER2 status (and/or HER2 categories) and efficacy/activity outcomes (objective response per RECIST v1.1, progression-free survival, overall survival) will be assessed.

    Time frame: 24 month

  10. Quality of life as assessed by the European Organization for Research and Treattment of Cancer (EORTC) QLQ-C30

    Quality of life will be assessed through Patients reported outcomes (completion of quality-of-life questionnaires, European Organization for Research and Treattment of Cancer (EORTC) QLQ-C30 during treatment). Questionnaires will be administered at baseline, every 9 weeks +/- 7 days during treatment and at the end of treatment.

    Time frame: 24 months

  11. CA19.9 dynamics

    Serum carbohydrate antigen 19-9 (CA19-9) concentration will be measured in peripheral blood using standard-of-care clinical laboratory immunoassays performed at participating sites. The unit of measure will be U/mL. CA19-9 kinetics will be summarized as: (i) absolute CA19-9 values (U/mL) over time; (ii) change from baseline (absolute and percent change); and (iii) CA19-9 normalization (conversion to within institutional normal range) when applicable. CA19-9 dynamics will be assessed at baseline, every 9 (+/- 1) weeks during treatment, at EOT and during follow-up visits through 24 months. Associations will be explored between CA19-9 kinetics and efficacy/activity outcomes including objective response (per RECIST v1.1), duration of response, progression-free survival and overall survival, using correlation/association analyses.

    Time frame: 24 months

  12. Quality of life as assessed by the European Organization for Research and Treattment of Cancer (EORTC) QLQ-CR-29

    Quality of life will be assessed through Patients reported outcomes (completion of quality-of-life questionnaires, European Organization for Research and Treattment of Cancer (EORTC) QLQ-CR-29 during treatment). Questionnaires will be administered at baseline, every 9 weeks +/- 7 days during treatment and at the end of treatment.

    Time frame: 24 months

  13. Quality of life as assessed by the European Organization for Research and Treattment of Cancer (EORTC) EuroQol EQ-5D

    Quality of life will be assessed through Patients reported outcomes (completion of quality-of-life questionnaires, European Organization for Research and Treattment of Cancer (EORTC) EuroQol EQ-5D during treatment). Questionnaires will be administered at baseline, every 9 weeks +/- 7 days during treatment and at the end of treatment.

    Time frame: 24 months

07

Study locations

28 of 28 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — The trial results concerning the primary, secondary and exploratory outcomes will be published according to the standard guidelines. IPD could eventually be requested to the Sponsor and Principal Investigator, who will carefully evaluate the formal and motivated request

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Oct 2027, 24 months after the start.

Of 499 non-industry phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 75. This study's planned 24 months is below that.

Counting every sponsor, half of 619 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2025
First posted
Feb 12, 2026
StartActual
Oct 20, 2025
Primary completionEst.
Oct 20, 2027
CompletionEst.
Oct 20, 2027
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07407465
Lead sponsor
Gruppo Oncologico del Nord-Ovest
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Feb 12, 2026
Start date
Oct 20, 2025
Primary completion
Oct 20, 2027 (estimated)
Completion
Oct 20, 2027 (estimated)
Last update
Feb 17, 2026

Study contacts

Filippo Pietrantonio, MD
Contact
filippo.pietrantonio@istitutotumori.mi.it
0039-3407683357
Federica M Palermo, Dr
Contact
chimerastudy@istitutotumori.mi.it
Filippo Pietrantonio, MD
principal investigator · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Trastuzumab deruxtecan · Capecitabine · Bevacizumab

Start the discussion